The most rigorous trial of HBOT for cerebral palsy, a 2001 Lancet study of 111 children, found no difference between hyperbaric oxygen and sham air on any primary outcome. Both groups improved, which the investigators attributed to structured attention rather than oxygen. A second controlled trial in 2012 was stopped early for futility. Major systematic reviews do not support HBOT for CP. This article explains why, and what the evidence supports instead.
What Is Cerebral Palsy, and Why Was HBOT Proposed?
Cerebral palsy is a group of permanent movement and posture disorders caused by non-progressive damage to the developing brain, usually before, during, or shortly after birth. The damage may come from oxygen deprivation, infection, stroke, or brain malformation. The initial injury does not progress, but its effects on motor function and cognition evolve as the child develops.
The theoretical case for HBOT rested on the idea of dormant neurons: brain cells still alive but functionally idle due to chronic low-grade hypoperfusion around the primary injury. If such neurons existed and HBOT could reactivate them, function might improve. This is where the important distinction sits. CP involves permanent structural damage, not ongoing ischemia. The injured tissue is not waiting for oxygen. HBOT works mainly by improving oxygen delivery to ischemic but living tissue, so its theoretical fit with CP was always uncertain. Reports of increased cerebral blood flow on SPECT scans kept interest alive, but the dormant-neuron concept has never been validated in humans. This is one of several brain conditions where mechanism and marketing outran the trial evidence.
What Did the Landmark Cerebral Palsy Trial Find?
The most rigorous study was published in The Lancet in 2001 by Collet and colleagues.1 This Canadian randomized controlled trial enrolled 111 children with spastic CP and assigned them to either HBOT (1.75 ATA, 100% oxygen) or a sham treatment (1.3 ATA, slightly pressurized air). Both groups received 40 sessions of 60 minutes.
Both groups improved significantly on multiple functional outcome measures. There was no statistically significant difference between the HBOT and sham groups on any primary outcome. The investigators concluded the improvements were likely due to non-specific effects of the clinical environment, structured attention, and therapy, not the hyperbaric oxygen itself. That finding has not been superseded by any later trial.
The Two Controlled Trials of HBOT for Cerebral Palsy
| Study | Children (N) | Design | Result |
|---|---|---|---|
| Collet 2001 (Lancet) | 111 | HBOT vs sham (slightly pressurized air) | No between-group difference on any primary outcome |
| Lacey 2012 (Ann Neurol) | 49 | HBOT vs hyperbaric air | No difference on motor function; stopped early for futility |
Does HBOT Improve Motor Function in Cerebral Palsy?
No. Both controlled trials measured motor function directly, and neither found HBOT better than a control condition. The 2012 Lacey trial randomized 49 children aged 3 to 8 with spastic CP to 40 treatments of HBOT (100% oxygen at 1.5 atm) or hyperbaric air (14% oxygen at 1.5 atm) over 8 weeks.2 There was no change in the Gross Motor Function Measure in either group or between groups. Both groups improved modestly on a disability inventory, with no difference between them. The trial was stopped early because the calculated probability of finding any between-group difference if it continued was only 0.5% to 1.6%.
Two systematic reviews reached the same conclusion. McDonagh and colleagues (2007) reviewed the state of the evidence and found it did not support HBOT for CP,3 and a 2022 systematic review by Laureau and colleagues concluded that HBOT is not effective for improving function in children with cerebral palsy.4 Given the cost and the potential for harm, these reviews recommend against use outside research settings. Our neurological conditions guide covers where HBOT does have stronger support.
Should Parents Try HBOT for a Child With Cerebral Palsy?
A course of 40 sessions can cost $8,000 to $20,000 or more, and insurance rarely covers it for CP. Against that sits an evidence base that shows no specific benefit over the non-specific effects a structured, attentive clinical program already provides. This is not a comfortable message for motivated, loving parents, but it is the honest one.
Individual children do sometimes improve during or after HBOT. Distinguishing improvement caused by HBOT from improvement caused by intensive structured care, or from natural developmental progress, is genuinely difficult without controlled conditions. That is exactly why the sham-controlled design matters: when the sham group improves just as much, the oxygen is not the explanation.
For children with CP who have seizure disorders (a common comorbidity), HBOT can lower the seizure threshold and requires careful consideration. Younger children may also struggle to equalize ear pressure or tolerate long sessions in a confined chamber. The side effects guide covers oxygen toxicity and other general risks. If you decide to proceed despite the evidence, keep evidence-based therapies in place, set specific outcome measures before starting, and set a clear decision point after one course before committing to more.
What Are the Evidence-Based Alternatives to HBOT for CP?
Money and time spent on HBOT are not available for therapies with stronger evidence. For improving motor function in cerebral palsy, the following interventions have better support than HBOT:
- Intensive and goal-directed physical therapy
- Constraint-induced movement therapy (CIMT) for asymmetric involvement
- Botulinum toxin injections for focal spasticity
- Selective dorsal rhizotomy (SDR) for appropriate candidates
- Intrathecal baclofen for severe generalized spasticity
These belong at the center of a management plan, alongside educational support and family resources through networks such as the Cerebral Palsy Alliance and United Cerebral Palsy. HBOT, if pursued at all, should be a small and clearly-evaluated add-on, not the centerpiece. Our guide to HBOT for children puts pediatric use in context.
Frequently Asked Questions
If HBOT doesn’t work for CP, why do some families report improvement?
Several factors produce improvement that is not specific to HBOT: the intensive structured care during a treatment course, increased parental attention and engagement, natural developmental progress, and regression to the mean. In both controlled trials, the sham or control group improved just as much as the HBOT group, which is the strongest evidence that the oxygen itself is not responsible (Collet 2001; Lacey 2012).
Are there any CP subtypes where HBOT might be more justified?
Some researchers have suggested CP linked to white matter injury (periventricular leukomalacia) might respond better, on the theory that white matter could recover with improved oxygenation. This is speculative and is not supported by subgroup analyses from the controlled trials. It should not be presented to families as an established indication.
What are evidence-based alternatives for CP motor improvement?
Intensive physical therapy, constraint-induced movement therapy, botulinum toxin for focal spasticity, intrathecal baclofen for severe spasticity, and selective dorsal rhizotomy for appropriate candidates all have stronger evidence for improving motor function in CP than HBOT. These should be the priority for families weighing where to spend limited time and money.
Sources
- Collet JP, Vanasse M, Marois P, et al. Hyperbaric oxygen for children with cerebral palsy: a randomised multicentre trial. Lancet. 2001;357(9256):582-586. DOI: 10.1016/S0140-6736(00)04054-X. PMID: 11558483.
- Lacey DJ, Stolfi A, Pilati LE. Effects of hyperbaric oxygen on motor function in children with cerebral palsy. Annals of Neurology. 2012;72(5):695-703. DOI: 10.1002/ana.23681. PMID: 23071074.
- McDonagh MS, Morgan D, Carson S, Russman BS. Systematic review of hyperbaric oxygen therapy for cerebral palsy: the state of the evidence. Developmental Medicine & Child Neurology. 2007;49(12):942-947. DOI: 10.1111/j.1469-8749.2007.00942.x. PMID: 18039243.
- Laureau J, Pouplin S, Vermersch AS, et al. Hyperbaric oxygen in children with cerebral palsy: a systematic review of effectiveness and safety. PLoS ONE. 2022;17(10):e0276126. DOI: 10.1371/journal.pone.0276126. PMID: 36240157.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
